psalexa
P&S Market Research - A market research firm

Neurofibromatoses Therapeutics Pipeline Analysis

Neurofibromatoses Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11248
Available Format:

Neurofibromatoses is an inherited disorder that causes tumour formation in the supporting cells of the nervous system that make up the nervous system and myelin sheath. It can also produce abnormalities such as bone deformities and skin colour changes. There are three forms of neurofibromatoses. Neurofibromatoses type I is most common and usually evident in children below 10 years of age. Light brown spots on skin, tumour on the optic nerve, abnormal development of spine and skull bone, and two or more growth on the iris of the eye, are the characteristics observed in patients with neurofibromatoses type I. In case of neurofibromatoses type II, presence of vestibular schwannomas, tumours on vestibular branch of left and right eighth cranial nerve, is found. Neurofibromatoses type III is rare genetic disorder characterized by the presence of multiple schwannomas without the involvement of the vestibular nerves. The symptoms observed in patients are numbness, tingling, and pain. Universitaire Ziekenhuizen Leuven is in the process of developing lamotrigine as a sodium channel antagonist for the treatment of neurofibromatoses. Betta Pharmaceuticals Co., Ltd. is in the process of developing icotinib as an epidermal growth factor receptor and tyrosine kinase inhibitor for the treatment of neurofibromatoses. Some of the companies having the pipeline of neurofibromatoses include Betta Pharmaceuticals Co., Ltd., Novartis AG, AstraZeneca plc, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry